
Daily Derm Times: July 11, 2025
Key Takeaways
- Recent FDA approvals and pipeline developments are shaping the dermatology landscape in 2025, with significant implications for treatment options.
- GEP testing is enhancing personalized care in melanoma and SCC, moving beyond traditional staging methods.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
FDA News and Decisions: Midyear Updates
Exclusive Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first half of 2025.
How GEP Testing is Personalizing Skin Cancer Care Beyond Staging
At a recent Dermatology Times Case-Based Roundtable event, Gaurav Singh, MD, MPH, FAAD, FACMS, utilized 3 patient cases to explore the role of GEP testing in melanoma and SCC.
Scalp Disorders in SoC: A Diagnostic Blind Spot
A systematic review reveals critical diagnostic gaps in hair loss treatment for patients with skin of color, urging improved training and protocols in dermatology.
Upadacitinib Plus Excimer Laser Efficacious in Treating Refractory Vitiligo With Moderate to Severe Atopic Dermatitis
After 4 months of treatment with the dual therapy, patients with refractory vitiligo exhibited an overall 55% remission rate.
Ethanol-Based Hand Sanitizer Shows No Visible Dermal Toxicity; Further Testing Warranted
Ethanol-based hand sanitizer showed no visible skin toxicity in rats, but subclinical dermatitis raised concerns about dermal test guideline adequacy.
Think Like a CEO: Financial Tips for Physicians
OJM Group’s David Mandell, JD, MBA, shares financial planning strategies for physicians facing new tax laws and market volatility.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















